Assessment of Drug–Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects-Reference-Cited by-同舟云学术

Assessment of Drug–Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects

Published:2016-05-31 Issue:2 Volume:42 Page:309-318
ISSN:0378-7966
Container-title:European Journal of Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Eur J Drug Metab Pharmacokinet

Author:

Ayalasomayajula Surya,Pan Wei,Han Yi,Yang Fan,Langenickel Thomas,Pal Parasar,Zhou Wei,Yuan Yaozong,Rajman Iris,Sunkara Gangadhar

Funder

Novartis Pharma AG, Basel, Switzerland

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s13318-016-0349-y.pdf

Reference37 articles.

1. Entresto Prescribing Information. Highlights of Prescribing Information. (2015). US FDA http://www.pharma.us.novartis.com/product/pi/pdf/entresto.pdf . 12 Jan 2016.

2. Entresto Summary of Product Characteristics (2015). EMA https://www.medicines.org.uk/emc/medicine/31244 . 3 Feb 2016.

3. Bloch MJ, Basile JN. Combination angiotensin receptor blocker-neutral endopeptidase inhibitor provides additive blood pressure reduction over angiotensin receptor blocker alone. J Clin Hypertens (Greenwich). 2010;12(10):809–12.

4. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–14.

5. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail. 2014;2(6):663–70.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of muscular system adverse reaction signals in sacubitril/valsartan treatment combined with statins;Frontiers in Pharmacology;2024-07-15

2. Bioanalytical HPLC method with fluorescence detector for determination of Entresto™ when co-administered with ibuprofen and fexofenadine: a pharmacokinetic study;RSC Advances;2024

3. Approaches to management of rhabdomyolysis as the adverse effect of drug interaction between atorvastatin and sacubitril/valsartan: a case report;European Heart Journal - Case Reports;2022-02-22

4. Synchronized determination of sacubitril and valsartan with some co‐administered drugs in human plasma via UPLC–MS/MS method using solid‐phase extraction;Biomedical Chromatography;2021-06-29

5. Drug‐Drug Interaction Surveillance Study: Comparing Self‐Controlled Designs in Five Empirical Examples in Real‐World Data;Clinical Pharmacology & Therapeutics;2020-12-17